Agile Therapeutics (AGRX) Sees Strong Trading Volume

Share on StockTwits

Agile Therapeutics Inc (NASDAQ:AGRX) saw strong trading volume on Monday . 2,993,109 shares were traded during trading, an increase of 972% from the previous session’s volume of 279,165 shares.The stock last traded at $0.91 and had previously closed at $0.89.

A number of analysts recently weighed in on the stock. Maxim Group restated a “buy” rating and set a $3.00 target price on shares of Agile Therapeutics in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Agile Therapeutics in a research note on Friday, January 11th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Agile Therapeutics has an average rating of “Buy” and an average price target of $3.33.

The company has a market cap of $30.60 million, a P/E ratio of -0.99 and a beta of 0.32.

A number of institutional investors have recently made changes to their positions in AGRX. Fosun International Ltd acquired a new stake in shares of Agile Therapeutics in the third quarter valued at approximately $180,000. Renaissance Technologies LLC boosted its holdings in shares of Agile Therapeutics by 76.3% in the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after acquiring an additional 343,290 shares during the period. BlackRock Inc. boosted its holdings in shares of Agile Therapeutics by 15.7% in the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after acquiring an additional 18,038 shares during the period. Finally, Acadian Asset Management LLC boosted its holdings in shares of Agile Therapeutics by 260.7% in the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock valued at $180,000 after acquiring an additional 226,255 shares during the period. Institutional investors own 41.92% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Agile Therapeutics (AGRX) Sees Strong Trading Volume” was originally posted by Macon Daily and is owned by of Macon Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://macondaily.com/2019/02/11/agile-therapeutics-agrx-sees-strong-trading-volume.html.

Agile Therapeutics Company Profile (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Story: Moving Average (MA)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply